Familial Transthyretin AmyloidosisSymptoms, Doctors, Treatments, Advances & More
Familial Transthyretin Amyloidosis Overview
Learn About Familial Transthyretin Amyloidosis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Perelman Center For Advanced Medicine South Pavilion, 2nd Floor
Chafic Karam is a Neurologist practicing medicine in Philadelphia, Pennsylvania. Dr. Karam is rated as an Elite provider by MediFind in the treatment of Familial Transthyretin Amyloidosis. He is also highly rated in 55 other conditions, according to our data. His clinical expertise encompasses Transthyretin Amyloidosis, Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Tissue Biopsy, and Laminectomy. Dr. Karam is currently accepting new patients.
Dysautonomia Center LLP
Maria Gonzalez is a Neurologist practicing medicine in New York, New York. Dr. Gonzalez is rated as an Elite provider by MediFind in the treatment of Familial Transthyretin Amyloidosis. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Primary Amyloidosis, Familial Transthyretin Amyloidosis, Transthyretin Amyloidosis, and Familial Dysautonomia.
CUIMC/Vivian & Seymour Milstein Family Heart Center
Mathew S. Maurer, MD - Dr. Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer is a member of the Advanced Cardiac Care Center at NewYork Presbyterian Hospital – Columbia Campus. He is the Director of the Cardiac Amyloidosis Program. He has published over 300 articles including peer reviewed manuscripts, reviews and book chapters. He was Chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organization dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy. Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately afflict older adults. Dr. Maurer is rated as an Elite provider by MediFind in the treatment of Familial Transthyretin Amyloidosis. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Cardiac Amyloidosis, Primary Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Heart Transplant, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Maurer is board certified in Internal Medicine, Cardiovascular Disease, and Advanced Heart Failure And Transplant Cardiology. Dr. Maurer is currently accepting new patients.
Summary: This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
Summary: This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
